Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Rectal Neoplasms 1Prostatic Neoplasms 1Osteoarthritis 1Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cancer Pain 1Brain Stem Neoplasms 1Brain Neoplasms 1Barrett Esophagus 1Advanced Non-small Cell Lung Cancer 1Adenomatous Polyposis Coli 1

Interventions

Fluorouracil 267Oxaliplatin 266Capecitabine 224Leucovorin 209Irinotecan 151Radiotherapy 131Bevacizumab 112Cetuximab 81Folfox protocol 48Surgical Procedures, Operative 44Radiation 41Drug Therapy 41Neoadjuvant Therapy 40Chemoradiotherapy 33Chemotherapy, Adjuvant 32Panitumumab 27XELOX 25Magnetic Resonance Spectroscopy 22Radiotherapy, Intensity-Modulated 21Floxuridine 17Biopsy 16Nivolumab 15Gemcitabine 15Early Intervention, Educational 15pembrolizumab 14Laparoscopy 14IFL protocol 14Celecoxib 14trifluridine tipiracil drug combination 13Gene Expression Profiling 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rectal Neoplasms × rofecoxib × Clear all
NCT00031863 2013-08-02

Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡